Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Raloxifene (Evista) vs Red Clover: Red Clover has the stronger overall evidence (7.5 vs 5.3/10); they're alternatives for bone health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Red Clover wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Likely helps
13 of 15 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Raloxifene (Evista) and Red Clover have evidence — compare verdict strength side-by-side.
Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the MORE, CORE, RUTH and STAR trials all used 60 mg/day; MORE also tested 120 mg/day with no clear added fracture benefit and more side effects). For off-label male gynecomastia the small published pediatric series used roughly 60 mg/day; there is no FDA-approved male dose and the male evidence is thin and retrospective.
any
Raloxifene hydrochloride 60 mg tablets (approved for postmenopausal osteoporosis and breast-cancer risk reduction)
40-80mg isoflavones daily
With meals, Consistent daily timing
Standardized extract (40mg isoflavones per dose)
Months to years
Years
Throughout use
Throughout use
4-12 weeks
6-12 months
8-12 weeks
Ongoing
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
JAMA (1999) · Rct · n=7705
MORE: multicenter, randomized, double-blind, placebo-controlled trial of raloxifene 60 or 120 mg/day in 7,705 postmenopausal women with osteoporosis, followed up to 36 months
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
JAMA (1999) · Rct · n=7705
Pre-specified breast-cancer analysis of the MORE RCT (7,705 postmenopausal women with osteoporosis), followed a median 40 months
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
J Natl Cancer Inst (2004) · Rct · n=5213
CORE: extension of the randomized MORE trial giving 4 additional years of raloxifene 60 mg/day (n=3,510) vs continued placebo (n=1,703)
The effectiveness of nutritional supplements in improving polycystic ovary syndrome in women: a systematic review and network meta-analysis
Reproductive biology and endocrinology : RB&E (2025) · Meta analysis · n=5501
Inositol significantly decreased total cholesterol and triglyceride levels, while curcumin was most effective in improving low-density and high-density lipoprotein cholesterol levels.
Role of Phytoestrogen-Rich Bioactive Substances (Linum usitatissimum L., Glycine max L., Trifolium pratense L.) in Cardiovascular Disease Prevention in Postmenopausal Women: A Systematic Review and Meta-Analysis
Nutrients (2022) · Meta analysis
The effect of soy protein on the lipid profile showed a significant decrease in TC levels: WMD = -0.15; 95% CI: -0.25-0.05; p = 0.0048, LDL-C levels: WMD = -0.15; 95% CI: -0.25-0.05; p = 0.0067, as well as a significant increase in HDL-C levels: WMD = 0.05; 95% CI: 0.02-0.08; p = 0.0034.
Neither soy nor isoflavone intake affects male reproductive hormones: An expanded and updated meta-analysis of clinical studies
Reproductive toxicology (Elmsford, N.Y.) (2021) · Meta analysis · n=752
Sub-analysis of the data according to isoflavone dose and study duration also showed no effect.
Based on meta-analysis showing statistically moderate reduction in daily hot flash frequency. Effect size is modest and individual response varies significantly.
AI-estimated from published studies. Interpret as directional guidance.
Red Clover has a higher evidence score (7.5/10 vs 5.3/10) and wins in 3 of 3 categories.
For bone health, Raloxifene (Evista) has a higher relevance score (76 vs 72).
No known interactions between Raloxifene (Evista) and Red Clover have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.